This partnership is a patient advocacy and care-enabling initiative, not a commercial or clinical catalyst. Traders should monitor for future updates on pociredir’s clinical development or regulatory progress as the primary value drivers. No immediate financial impact is expected.
Price Chart
Executive Summary
Fulcrum Therapeutics (FULC) announced a partnership with MedicAlert Foundation and the Sickle Cell Disease Association of America (SCDAA) to expand access to emergency medical information for sickle cell disease (SCD) patients via MedicAlert’s Smart Medical ID Cards. The program links patient-specific care plans to QR codes, enabling faster clinical decisions during ED visits. Fulcrum is funding the expansion but no financial terms were disclosed.
Key Facts
- Fulcrum Therapeutics partnered with MedicAlert and SCDAA to expand emergency care access for sickle cell disease patients.
- The program provides patients with a MedicAlert Smart Medical ID Card that links to a digital health profile containing pain plans, medications, allergies, and hematologist contacts.
- No financial terms, dollar amounts, or share impacts were disclosed.
- This is a non-commercial, patient-support initiative aimed at improving care coordination, not a product launch or regulatory event.
- Fulcrum’s lead candidate, pociredir, remains in clinical development for SCD.
Financial Impact
Unknown — no financial terms disclosed
Risk Factors
- No measurable financial or clinical benefit to Fulcrum from this program
- Potential for increased operating expenses if funding is significant
- No assurance of improved patient outcomes or adoption in emergency settings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258908 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.68%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.43%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.13%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+4.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.38%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access